Veradigm Sees FY23 Non-GAAP EPS $0.79-$0.88
Portfolio Pulse from Benzinga Newsdesk
Veradigm, a healthcare information technology solutions unit, has provided its fiscal year 2023 non-GAAP earnings per share (EPS) guidance to be in the range of $0.79 to $0.88.
January 10, 2024 | 1:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Veradigm, associated with Allscripts Healthcare Solutions (MDRX), has issued its FY23 non-GAAP EPS guidance, which could influence MDRX's stock performance.
The guidance provided by Veradigm is a key indicator of its financial health and future performance. As Veradigm is a part of Allscripts Healthcare Solutions, this positive earnings guidance is likely to reflect favorably on MDRX's stock in the short term, as it suggests operational efficiency and potential growth in profitability.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80